Sign up
Pharma Capital

Red letter day for Summit Therapeutics after positive interim ezutromid results

Proactive Investors' editor Ian Lyall reports on the release this afternoon by Summit Therapeutics PLC (LON:SUMM,NASDAQ:SMMT) of encouraging data for its treatment for Duchenne Muscular Dystrophy (DMD).

The interim results for the PhaseOut study revealed a “statistically significant and meaningful” reduction in muscle damage in patients taking the company’s treatment, ezutromid.

Duchenne Muscular Dystrophy is a rare muscle-wasting disease that affects boys.

 

View full SUMM profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.